Earnings Call Intelligence Subscribe
Home › Call Sheets › EW › Q4'25
Call sheet · Q4'25

Edwards Lifesciences (EW)

Q4'25 earnings call · held February 10, 2026 · compared with the Q3'25 call · management-credibility review
9/12
Disclosure score
2 medium, 4 low flags
Financial quality
Bottom line
**The sleeper story is Edwards' SG&A surge**: that $112M Q4 jump isn't 'strategic investment' but a sign they're fighting harder for TAVR share than their 'stable competitive position' narrative suggests. The 7-year durability data was impressive, but management's focus on 'lifetime management' reveals they're already worried about valve-in-valve competition. **The binding constraint isn't demand - it's that Edwards has no clear M&A pipeline** despite $2B in buyback authorization and a dead GennaValve deal, while Scott Ullem's departure signals strategic uncertainty at the top. As Bernard said, 'we decided to be aggressive' in Q4 spending - that's not the language of a comfortable market leader. **My view changes if** Q1 SG&A normalizes below $550M and they announce a credible M&A target.

The 30-second version

  • The SG&A Surge: $112M YoY Q4 Jump Signals TAVR Market Share War
  • TAVR Guidance Confidence Despite Tough Comps Masks Duration Risk
  • GennaValve Pullback Leaves $2B Cash Burning a Hole

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$1.55B (+12.6% YoY)$1.57B (+11.6% YoY)Growth deceleration of 100bps
TAVR Revenue$1.15B (+10.6% YoY)$1.16B (+10.6% YoY)Growth rate maintained
TMTT Revenue$144M (+53% YoY)$156M (+40% YoY)Growth deceleration of 1300bps
Surgical Revenue$258M (+5.6% YoY)$254M (+2% YoY)Growth deceleration of 360bps
Adjusted EPS$0.67 (well above expectations)$0.58 (lower than expected)13% sequential decline
SG&A Expense$515M (33.1% of sales)$603M (38% of sales)+$112M YoY jump, 490bps margin hit
Adjusted Gross Margin77.9%78.3%+40bps improvement
Operating Margin27.5%23.7%380bps compression
Full-Year Sales GrowthRaised to high end of 9-10%10.7% actualDelivered on raised guidance
2026 TAVR Guidance6-7% range6-8% range (increased confidence)Upper bound raised 100bps

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full EW Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.